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Successful thrombolytic therapy is associated with an accelerated 
release of creatine kinase (CK) MB from necrotic myocardium. 
With use of a previously validated assay, the plasma kinetics of the 
myocardial subform (MBz) and the plasma· modified subform 
(MB t ) were determined in blood samples obtained from 56 
patients with acute Q wave myocardial infarction: 33 patients who 
received thrombolytic therapy (group A) and 23 patients managed 
conservatively (group B). 
Plasma MBz activity increased more rapidly in the group A 
patients, but there was substantial overlap with group B. Plasma 
MB t activity did not dift'er significantly between the two groups. 
The MBzlMB t ratio was significantly higher in group A patients 
than in group B patients between 2 and 10 h after the onset of 
infarction. Among group A patients, the ratio increased from 
2.4 ± 1.6 to 4.6 ± 2.0 in the 1st h after therapy (p < 0.001). The 
peak ratio was 6.3 ± 2.5 in group A patients and 3.1 ± 1.2 in 
group B patients. Twenty·seven of the 33 group A patients had a 
Intravenous administration of a thrombolytic agent is now 
standard practice for the treatment of patients presenting in 
the early hours of an acute Q wave myocardial infarction. 
Such therapy restores coronary artery patency in about 75% 
of patients (1-3). Because there is currently no reliable 
noninvasive marker of successful recanalization of the 
infarct-related artery, patients who might benefit from early 
"salvage" angioplasty cannot be identified unless all pa-
tients receiving thrombolytic therapy undergo acute coro-
nary angiography. 
We (4) have developed an assay that accurately quantifies 
the two subforms of creatine kinase (CK) MB (4) and have 
shown (5) that changes in the plasma activity of these 
subforms occur before conventional CK MB assays exceed 
the normal range, permitting the reliable diagnosis of acute 
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peak ratio >3.8 versus 5 of the 23 group B patients (p < 0.001). 
In seven group A patients, the ratio was >3.8 before plasma CK 
MB activity was out of the normal range. 
Angiography was performed at 5.0 ± 3.5 days in 39 patients. 
Eighteen (90%) of 20 patients with a patent infarct·related artery 
had a peak ratio >3.8; 17 (89.5%) of 19 patients with an occluded 
infarct·related artery had a ratio <3.8 (p < 0.001). 
The MBzlMBt plasma subform activity ratio reflects coronary 
artery patency within 1 to 2 h of intravenous thrombolytic 
therapy. This technique shows promise as a tool for rapidly 
identifying patients with an occluded infarct·related artery who 
might benefit from "salvage" angioplasty and avoiding catheter· 
ization in the majority of patients with a patent vessel. It might 
also be useful as an end point in trials comparing alternative 
thrombolytic regimens. 
(J Am Coll CardioI1991;17:1047-52) 
myocardial infarction within 5 h of symptom onset. Because 
successful reperfusion is known to be associated with an 
accelerated release of CK MB from necrotic myocardium 
(6,7), we measured the ratio ofthe tissue subform MB2 to the 
plasma-modified subform MB 1 in a group of patients with 
acute Q wave myocardial infarction who had been treated 
with intravenous recombinant tissue-type plasminogen acti-
vator (rt-PA) and compared the results with those obtained 
in patients treated without a thrombolytic agent. We show 
here that this ratio can be used to discriminate between 
reperfused and nonreperfused acute myocardial infarction. 
Methods 
Study patients. The study group consisted of 56 consec-
utive patients ~75 years of age admitted to The Methodist 
Hospital within 6 h of the onset of prolonged (~30 min) chest 
discomfort typical of myocardial ischemia and ~ 1 m V of ST 
segment elevation in two contiguous electrocardiographic 
(ECG) leads. Patients gave written informed consent to the 
protocol, which was approved by the Baylor College of 
Medicine Institutional Review Board. 
Thirty-three patients (group A) received intravenous 
rt-PA within 6 h of symptom onset, with an initial bolus 
injection of 6 mg followed by an infusion of 54 mg in the 
0735-1097/91/$3.50 
1048 PULEO AND PERRYMAN 
CREATINE KINASE MB SUB FORMS IN REPERFUSION 
JACC Vol. 17, No.5 
April 1991 ;17: 1047-52 
Table 1. Plasma Subform Activity Versus Time Mter Symptom Onset 
Hours After Symptom Onset 
0-2 2-4 4-6 6-8 8-10 1O-I2 12-14 14-16 
MB2 subform activity 
(U/liter) 
Group A (pre) 1.6 ± 2.8 2.8 ± 4.0 18 ± 23 
Group A (post) 0.8 ± 1.I 8.5 ± 10 26 ± 39 45 ± 62 66 ± 54' 40 ± 25 36 ± 28 35 ± 17 
Group B 0.5 ± 0.1 1.8 ± 1.5 20 ± 30 15 ± 24 17 ± 22 27 ± 28 24 ± 14 28 ± 18 
MBI subform activity 
(Ulliter) 
Group A (pre) 0.9 ± 1.I 0.9 ± 0.9 5.1 ± 8.3 
Group A (post) OJ ± 0.5 1.6 ± 1.6 503 ± 7.6 10 ± 16 18 ± 20 I3 ± 9 16 ± 17 22 ± 20 
Group B 0.4 ± OJ 0.6 ± 0.5 603 ± 9.0 4.0 ± 4.9 603 ± 8.9 1I±I3 II ± 7 17 ± I3 
*p < 0.01 versus Group B. Group A = 33 patients who received thrombolytic therapy; group B = 23 patients who did not receive thrombolytic therapy; post 
= samples obtained from group A patients after the administration of therapy; pre = samples obtained from group A patients before the administration of therapy. 
1st h, 20 mg in the 2nd hand 5 mg/h for the next 4 h (total 
dose 100 mg in 6 h). Anticoagulant therapy with intravenous 
heparin was initiated after the completion of the rt-PA 
infusion. The remaining 23 patients (group B) had a contrain-
dication to or refused thrombolytic therapy. Plasma samples 
for isoenzyme and subform analysis were obtained at the 
time of hospital admission, at 2 h intervals for the next 6 h 
and every 4 h thereafter for 24 h. The need for and timing of 
coronary arteriography were determined by each patient's 
attending physician. Arteriograms were performed and in-
terpreted by the attending physician, who did not know the 
results of the subform assay. 
Isoenzyme and subform determinations. Plasma total CK 
activity was assayed by the method of Rosalki (8). Plasma 
CK MB activity was determined using a batch adsorption 
assay (9) (Lancer MB CK Isoenzyme Separation System); 
this method is used for routine clinical CK MB determina-
tions in our institution. Plasma MB2 and MB) subform 
activity and the MB2/MB) activity ratio were quantitatively 
determined by high voltage electrophoresis (Rep, Helena 
Laboratories), as previously described (4). The subform 
assay system is sensitive to 0.5 Ulliter of CK MB activity. 
Assay time is 25 min. 
Statistics. Comparisons in MB subform activity among 
group A before therapy, group A after therapy and group B 
were performed by analysis of variance. Differences in the 
MB2/MBI subform activity ratio from group A patient sam-
ples obtained before therapy versus those obtained after the 
start of therapy were made using a paired two-tailed t test. 
The significance of differences between group A and group B 
in patient demographics and number of patients above and 
below the cutoff ratio was assessed by chi-square analysis. 
Similarly, the significance of differences between patients 
with a patent infarct-related artery and those with an oc-
cluded infarct-related artery and the number of patients 
above and below the cutoff value was assessed by chi-square 
analysis. 
Results 
Groups A and B did not differ significantly with respect to 
age, gender, anatomic location of infarction or the propor-
tion of patients receiving aspirin, nitrates, calcium antago-
nists or beta-receptor antagonists within 24 h of admission. 
Subform activity. The mean plasma MB2 and MB) activ-
ity through 16 h after symptom onset is shown in Table 1. 
Plasma samples were obtained from 29 of the 33 group A 
patients before the initiation of treatment; data from these 
samples are presented separately. The mean time to the 
initiation of treatment in group A was 2.46 ± 1.33 h. Samples 
obtained from group A patients after treatment exhibited 
higher mean MB2 and MBI activity than samples obtained 
from group B patients in the corresponding time intervals 
throughout most of the period encompassed by the study. 
However, the wide variation in subform activity during each 
time interval resulted in substantial overlap between the 
groups; consequently, there was no significant difference in 
plasma MB2 or MB) activity between group A and group B 
at any time interval except between 8 and lO h after 
symptom onset, when mean MB2 activity in the treated 
group reached its highest value. 
Subform ratio. The MB2/MB) plasma activity ratio in 
samples obtained between 2 and 10 h after symptom onset 
was significantly higher in group A patients than in group B 
patients (Fig. I). The MB2/MB) ratio in samples obtained 
from patients in group A before the initiation of therapy was 
not significantly different from the subform ratio in samples 
obtained over the same time intervals from patients in group 
B. 
The relation of the MB2/MBI plasma activity ratio to the 
time after the initiation of treatment among the group A 
patients is shown in Figure 2. The subform ratio increased 
almost two-fold in the first hour after treatment and re-
mained significantly greater than pretreatment levels for 7 h. 
The highest mean subform ratio was 6.0 ± 2.3 in the samples 
obtained between 1 and 2 h after the initiation of treatment. 
JACC Vol. 17, No.5 
April 1991 ;17: 1047-52 
6 
.2 
5 
iii 4 a: 
,... 
m 3 
:E 
...... 
N 2 m 
:E 
0 
0 
-e- Group A (pre rx) 
____ Group A (post rx) 
__ Group B 
4 8 12 
Time (hours after onset) 
Figure 1. The MB2/MBI plasma subform activity ratio plotted 
against time after symptom onset. The time to treatment for group A 
patients was 2.46 ± 1.33 h. Samples obtained from group A patients 
before thrombolytic therapy (pre rx) and after thrombolytic therapy 
(post rx) are displayed separately. Group B did not receive throm-
bolytic therapy. *p < 0.01 versus group Band p < 0.01 versus group 
A patients before thrombolytic therapy; tp < 0.01 versus group B; 
tp < 0.05 versus group B. 
The peak MB2/MBI ratio was 6.3 ± 2.5 (range 2.6 to 15.9) 
in group A patients and 3.1 ± 1.2 (range 2.1 to 8.1) in group 
B patients (p < 0.01). A peak ratio of 3.8 provided maximal 
segregation of the patients in the two groups (Table 2). 
Twenty-seven (81.8%) of the 33 group A patients had a peak 
ratio >3.8. In contrast, only 5 (21.7%) of the 23 patients in 
group B had an MB2/MBI ratio >3.8 (p < 0.001). 
Angiographic findings. Coronary arteriography was per-
formed in 39 patients (26 in group A and 13 in group B) at 5.0 
± 3.5 days (range 0 to 11) after infarction. The peak 
MB2/MBI subform ratio was 6.4 ± 2.7 (range 3.3 to 15.9) 
among the patients with a patent infarct-related vessel and 
3.0 ± 1.3 (range 2.1 to 5.7) among the patients with an 
occluded infarct-related vessel (p < 0.01). The cutoff value 
of 3.8 correctly segregated 18 (90%) of 20 patients having a 
patent infarct-related artery and 17 (89.5%) of 19 patients 
with an occluded infarct-related vessel (p < 0.001) (Table 3). 
There was no difference in the agreement between the 
Figure 2. The MB/MBI plasma subform activity ratio plotted 
against time after the administration of rt-PA in group A patients. 
*p < 0.001 versus before thrombolytic therapy. 
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Table 2. Segregation of Treatment Groups by Subform Ratio 
Group A 
Group B 
p < 0.001. 
27 
6 18 
1049 
MB2/MB I ratio and angiographic findings in patients under-
going catheterization in the 1st 5 days after myocardial 
infarction and those undergoing angiography between 6 and 
11 days. Of the six patients who received thrombolytic 
therapy and had an MB2/MBI ratio <3.8, four underwent 
coronary angiography; three had an occluded infarct-related 
artery. Of the five patients who did not receive thrombolytic 
treatment and had an MB2/MB I ratio> 3.8, three underwent 
coronary angiography; all three had a patent infarct-related 
artery. 
Time course of MB2/MB. elevation. Among the 27 group 
A patients in whom at least one plasma sample exhibited an 
MBz/MBI ratio >3.8, the ratio remained >3.8 for 8.8 ± 
2.1 h after treatment. The first posttreatment plasma sample 
was> 3.8 in 21 (77.8%) at a mean of 1.2 h after the initiation 
of treatment and 3.8 h after symptom onset. Among the 
remaining six patients, five had a second plasma sample in 
which the MB2/MBI ratio was> 3.8 at a mean of 2.9 h after 
the initiation of treatment. One patient had three samples at 
1.25,3.25 and 5.25 h after treatment, in which the ratio was 
<3.8, followed by a sample at 7.25 h after treatment in which 
the ratio was 4.10. Two group A patients had a ratio> 3.8 
before treatment was initiated. Among the five group B 
patients who had one or more plasma samples with a 
subform ratio> 3.8, the ratio did not exceed the cutoff value 
until 8.75 ± 3.71 h after symptom onset. 
CK MB isoenzyme activity. To ascertain whether the 
group A patients whose first posttreatment blood sample 
exhibited an MB2/MBI ratio <3.8 had rapid release of CK 
MB that was not reflected by the subform ratio, the change 
in CK MB activity during the interval from the initiation of 
treatment to the time of the first posttreatment samples was 
determined. The mean total CK MB activity in the first 
posttreatment plasma sample from these patients was 67 ± 
27 U/liter (range 43 to 120, upper normal limit 120 U/liter); 
the mean CK MB activity by a conventional assay (per-
formed on the same plasma samples independently of the 
subform assays) was 4.4 ± 4.9 Ulliter (range 0 to 12, upper 
normal limit 14). Both total and CK MB plasma activity were 
within the normal range in all samples, indicating that the 
Table 3. Segregation of Infarct-Related Vessel Patency by 
Subform Ratio 
Infarct-Related Artery 
Patent 
Occluded 
p < 0.001. 
18 
2 
2 
17 
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failure of the subform ratio to exceed 3.8 was not due to 
rapid CK washout that was not manifested by an increase in 
the plasma subform ratio. Among the 21 group A patients 
whose first posttreatment plasma sample had an MB2/MB I 
ratio> 3.8, 7 had an increase in plasma CK MB activity of 
<10 Ulliter from the pretreatment value. 
Discussion 
The present study demonstrates the potential of CK MB 
subform analysis for providing early noninvasive determina-
tion of the patency of the infarct-related artery in patients 
with acute myocardial infarction treated with an intravenous 
thrombolytic agent. The subform ratio increased more rap-
idly and to a higher level in patients receiving thrombolytic 
therapy than in untreated patients. A cutoff value could be 
established that permitted early separation of the treated 
patients from the untreated patients. These findings were 
confirmed by data from patients undergoing coronary angi-
ography before hospital discharge. 
Subform kinetics. The unmodified form of the MB isoen-
zyme, MB2, is present within myocytes (10). Release of CK 
and other macromolecules from infarcting myocardium re-
quires severe dysfunction or complete breakdown of the 
myocardial sarcolemma and in human patients is taken to be 
diagnostic of myocardial infarction (11). Egress of CK from 
the tissue into the blood probably occurs by means of the 
myocardial lymphatics (12). In reperfused infarction, the 
rate of CK release is abruptly increased (6.7), probably as a 
consequence of the acute increase in blood flow to the region 
of necrosis. An acceleration in membrane breakdown with 
reperfusion may also playa role. The role of collateral blood 
flow and the relative contribution of CK from the periphery 
of the infarct region versus the center of the infarct zone are 
unknown. 
Conversion of MB2 to the modified subform MB I occurs 
in the blood by the action of carboxypeptidase-N, probably 
by cleavage of the C-terminal lysine from the M subunit 
(13,14). On release of CK MB from necrotic myocardium, 
plasma MB2 activity begins to increase; simultaneously, 
conversion to MBI begins. Thus, the MB2/MBI ratio is 
determined by the rate of CK release and the rate of 
conversion of MB2 to MB I' as well as by the clearance rates 
of the two subforms from plasma. Preliminary data from our 
laboratory suggest that the two subforms are cleared from 
the blood at identical rates in the dog. With the sudden 
increase in MB2 typical of reperfused infarction, the rate of 
MB2 accumulation exceeds the rate of conversion to MBI 
and the MB2/MBI ratio is high. In contrast, nonreperfused 
infarction is characterized by a slower rate of CK release and 
a more gradual increase in plasma CK MB activity; as a 
result, a greater proportion of newly released MB2 is con-
verted to MB 1, resulting in a lower MB2/MBI ratio relative to 
that observed after reperfusion. Although plasma carboxy-
peptidase-N activity has been shown to increase by up to 
43% within 96 h of acute myocardial infarction, no significant 
JACC Vol. 17, No.5 
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changes occur in the initial hours after onset of infarction 
(15); consequently, this increase is unlikely to have an 
impact on the determinations made in this study. The effects 
of congestive heart failure, cardiogenic shock and systemic 
illness (such as renal failure) on carboxypeptidase activity 
and the rate of MB conversion are not well studied. Because 
there is significant individual variation in baseline plasma 
carboxypeptidase-N activity (15), it is possible that further 
refinement of the cutoff value suggested by our data may be 
attained by incorporating each patient's plasma carboxypep-
tidase activity into the diagnostic algorithm. 
Limitations. Although the MB2/MBI ratio was >3.8 in 
only 81.8% of the treated patients, the true sensitivity of the 
assay for reperfusion is probably significantly higher because 
the anticipated rate of therapeutic success for the regimen 
employed in our patients is only 70% to 80% (1-3). The 90% 
correlation with angiographic findings probably provides a 
closer estimate of the sensitivity of the technique. However, 
coronary angiography was not performed immediately after 
therapy in our patients. Approximately 10% of patients with 
an infarct-related artery that is patent immediately after 
thrombolytic therapy develop reocclusion before discharge 
(16). Although this may have accounted for the 10% of 
patients with a subform ratio >3.8 whose infarct-related 
artery was occluded at the time of coronary angiography, 
this cannot be stated with certainty in the absence of acute 
angiography. Similarly, the finding of an MB2/MBI ratio 
above the cutoff value in 21.7% of untreated patients likely 
reflected, at least to some degree, spontaneous reperfusion 
in some of these patients. The proportion of patients having 
a ratio> 3.8 among the untreated patients and the relatively 
greater time from symptom onset to peak subform ratio in 
these patients (8.75 h) were in agreement with the expected 
rate of spontaneous reperfusion in conventionally treated Q 
wave myocardial infarction (17). This hypothesis is sup-
ported by the stronger concordance of a peak subform ratio 
<3.8 with the presence of an angiographically occluded 
infarct-related vessel (89.5%) than with conservative therapy 
(78.3%). 
Other noninvasive markers of reperfusion. Two recent 
studies (18,19) employing acute coronary angiography im-
mediately after thrombolytic therapy documented an accel-
erated increase in plasma CK MB activity within 1 h of the 
administration of a thrombolytic agent. In both of these 
studies, as well as in two smaller studies (20,21) of plasma 
CK MB subform kinetics in patients receiving intracoronary 
thrombolytic therapy, a significant change was detectable 
within 1 h of treatment. In our study, 71% of the treated 
patients whose subform ratio increased to >3.8 exhibited 
this increase within 75 min of treatment; the remaining 29% 
had a delayed increase in the MB2/MBI ratio. These figures 
are compatible with the reported (22,23) time course of 
vascular patency observed after intravenous thrombolytic 
therapy as determined by acute coronary angiography. 
The differences between our findings and those of the 
other studies in the time to the release of CK cannot be 
JACC Vol. 17, No.5 
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explained by a lack of analytic sensitivity of the subform 
assay because the technology used in the present study can 
accurately detect 0.5 U/liter of CK MB (upper normal limit 
14 U/liter). In addition, all seven patients having an MB21 
MB 1 ratio <3.8 within 2 h of symptom onset also manifested 
plasma CK MB activity that was still within the normal range 
by a sensitive conventional CK MB assay, excluding the 
possibility of CK release that was not detected by the 
subform assay. Thus, the criteria for reperfusion proposed 
by Garabedian et al. (18) and Lewis et al. (19) would also not 
have been satisfied in these patients. 
The somewhat later release of CK in some of our treated 
patients might indeed be explained by the lack of early 
coronary angiography. Coronary angiography requires the 
injection of dye into the coronary ostium at supraphysiologic 
pressures to permit adequate vessel visualization and dye 
flow. This might augment CK washout, especially in vessels 
that remain tightly stenotic after clot lysis, in which distal 
coronary perfusion pressure might be severely attenuated. 
Indeed, de Zwaan et al. (24) recently demonstrated that 
patients receiving intracoronary streptokinase and acute 
coronary angiography without successful reperfusion had a 
rate of CK MB release significantly more rapid than that 
observed in untreated control patients. An alternative expla-
nation could be that the rt-PA protocol employed in this 
study was a relatively conservative one, administered over a 
6 h infusion, rather than the more rapid intracoronary 
infusions used in the earlier studies. Administration ofrt-PA 
over a shorter period of time may be associated with a 
shorter time to reperfusion. 
Other studies (25,26), including one from our laboratory 
(27), employed the three subforms of the MM isoenzyme as 
markers of reperfusion. Two of these studies (25,26) de-
tected reperfusion as an earlier time to peak MM3/MM) 
ratio. Because the peak MM ratio occurred as long as 7 to 
9 h after therapy and because at least one determination 
subsequent to the highest value is necessary to establish the 
peak value, this method is unlikely to be useful other than as 
a retrospective tool. In addition, CK MM is present at very 
high activity levels in skeletal muscle and the MM subforms 
are elevated in the blood by a variety of conditions affecting 
skeletal muscle (28-30); consequently, these markers are not 
specific for myocardial infarction, particularly in the pres-
ence of intramuscular injection, cardiopulmonary resuscita-
tion or electrical cardioversion. Other markers of reperfu-
sion, including a decrease in ECG ST segment elevation, 
abrupt relief of chest pain and the occurrence of arrhythmias 
have been noted to occur with increased frequency in the 
setting of successful thrombolytic therapy, but none of these 
is sufficiently sensitive or specific to be clinically useful 
(31-33). 
Clinical implications. The clinical applications of CK MB 
subform analysis in patients receiving thrombolytic therapy 
remain to be explored. Although routine early coronary 
angiography and angioplasty for patients receiving throm-
bolytic therapy are not beneficial and may be deleterious 
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(34-36), the role of acute salvage angioplasty limited to 
patients having persistent occlusion of the infarct-related 
vessel despite thrombolytic therapy remains unclear. Such a 
strategy might be expected to result in a high rate of acute 
patency in the subgroup of patients who fail to have throm-
bolysis achieved by medical therapy (37). Currently, this 
approach can be pursued only if all patients undergo acute 
coronary angiography. Because the subform assay can be 
performed in 25 min and does not require serial sampling, it 
could be utilized to guide acute mechanical intervention in 
patients who show no evidence of reperfusion within 60 to 
90 min of the administration of therapy. 
All patients in our study who were subform-positive by 
2 h after treatment and who later underwent coronary 
angiography had a patent infarct-related vessel. The time to 
acute intervention could be further reduced by pre hospital 
administration of the thrombolytic agent. Such a protocol 
has been shown to permit initiation of therapy 40 to 75 min 
earlier than is feasible with in-hospital therapy (38,39). The 
combination of such a protocol with subform determination 
at 60 and 90 min after the start of treatment would permit 
noninvasive identification of the majority of patients in 
whom lysis is unsuccessful shortly after hospital arrival. 
Even allowing for the time required to perform the assay, 
candidates for mechanical intervention could be identified by 
2.5 to 3 h after the onset of infarction. The assay is 
commercially available and is performed at our institution on 
a 24 h "stat" basis. The need for a trained technician and 
rigorous quality control makes the assay in its current format 
poorly suited for "bedside" use in the coronary care unit. 
Subform results might also be utilized in predischarge 
risk stratification and work-up. Patients having successful 
reperfusion may have residual viable myocardium at risk in 
the distribution of the infarct-related artery and are conse-
quently at risk for reocclusion and reinfarction. Such pa-
tients might warrant a more aggressive predischarge evalu-
ation for residual ischemia and consideration of late 
intervention than patients in whom therapy was unsuccess-
ful. In contrast, routine invasive investigation may not be 
warranted in patients having an occluded infarct-related 
vessel unless there is evidence of new ischemia, such as 
recurrent angina or a positive exercise test (40). These 
applications of the isoenzyme subform assay are currently 
being evaluated prospectively at our institution. 
Finally, the strong agreement between the subform ratio 
and angiographic data presented here suggests a potential 
role for subform analysis as a tool in studies evaluating the 
efficacy of alternative thrombolytic regimens. This would 
dramatically reduce the number of patients and costs re-
quired to conduct such investigations because each patient 
would provide primary end point data, thus allowing statis-
tically valid conclusions to be drawn with far fewer patients 
than would be necessary if death is the primary end point 
and at a much lower cost than would be required if all 
patients undergo acute coronary angiography. 
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